Muireann Bolger

Key details

Muireann Bolger is deputy editor of World Intellectual Property Review and Life Sciences Intellectual Property Review in London, where she covers trademarks, brands, as well as wider developments across the intellectual property sector.

She regularly attends and covers major IP conferences around the world, reporting on the latest legal, commercial and policy developments and interviewing leading figures from across the sector. She has also co-authored industry reports with leading IP organisations, including the International Trademark Association (INTA).

She is the editor of the website’s Community & Inclusion channel and the annual Influential Women in IP list, which celebrates the achievements and contributions of leading women across the IP sector.

Originally from Ireland, Muireann has nearly two decades of experience reporting on brand developments, strategy, and wider business issues.

In her current role, she writes and edits news and analysis for an international audience of IP professionals, while also championing inclusion within the profession.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 415

Articles by Muireann Bolger

UK regulators no longer exempt from paying successful parties' costs
Pharma
The UK Supreme Court has ruled that regulators such as the Competition and Markets Authority should be required to pay the costs of a party successfully appealing against one of their infringement decisions.   26 May 2022
OptraHealth sues Invitae over genetic testing chatbot
Genetics
OptraHealth has filed a patent infringement lawsuit against Invitae that centres on the latter’s Gia chatbot that offers genetic testing and advice.   24 May 2022
USPTO urges Vidal review of Arthrex petition
Americas
The US Patent and Trademark Office has argued against a bid by medical device maker Arthrex, which wants recognition that an ex-interim acting director lacked the power to refuse to review its petition.   19 May 2022
Pharma
Natera has accused rival medical company CareDx of infringing two patents covering its “cell-free” DNA testing technology, Prospera.   17 May 2022
Pharma
The state of Israel has sued Teva Pharmaceuticals for $100 million over alleged unpaid royalties relating to its multiple sclerosis drug, Copaxone.   12 May 2022
Americas
Moderna has rejected claims that its COVID-19 vaccine violates the patent rights of two biopharma companies, arguing that its contract with the US federal government has conferred immunity.   10 May 2022
Pharma
US pharmaceutical and medical device industries have expressed concerns regarding the policies of several countries, according to the Office of the US Trade Representatives.   28 April 2022
Generics
BioMarin Pharmaceutical and MSD, have sued Aurobindo Pharmaceuticals for patent infringement in a dispute over the drug Kuvan, used to treat a rare genetic disorder.   26 April 2022
Pharma
Nova Chemicals has asked Canada’s top court to revisit a historic patent damages award of CAD$645 million won by Dow Chemical at the country’s federal court of appeal.   21 April 2022
Pharma
In a victory for Novartis, the Delhi High Court in India has issued a permanent injunction against two India-based companies which had allegedly sought to make a generic version of the Hepatitis C treatment, Revolade.   19 April 2022

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.